ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cardiovascular Diseases Stem Cell Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-11N17739
Home | Market Reports | Health| Health Conditions
Global Cardiovascular Diseases Stem Cell Therapy Market Research Report 2024
BUY CHAPTERS

Global Cardiovascular Diseases Stem Cell Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-11N17739
Report
October 2025
Pages:141
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
PHARMICELL
GenCell
Mesoblast Limited
BioCardia
Cedars Sinai
Heartseed
EmCell
BlueRock Therapeutics
Cellino Biotech
Stem Cells Transplant Institute
CCTRN
Help Therapeutics Co., Ltd.
Beijing Cellapy biotechnology Co., LTD
CardioCell

Cardiovascular Diseases Stem Cell Therapy Market

The global Cardiovascular Diseases Stem Cell Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Stem cells have the ability to treat sick veins when they touch the sick vein wall. They're also used to treat heart failure by turning into heart muscle cells if there is weakness in the heart muscles. They accelerates the post-operative recovery process by reinforcing the autoimmune system. They accelerate the treatment of heart muscle inflammation and inflammation. Endothelial stem cells (treating veins) are used for vessel walls. These stem cells are mostly derived from bone marrow. However, mesenchymal or fetal stem cells are used together to treat other factors affecting the disease.
From a downstream perspective, Preclinical accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Cardiovascular Diseases Stem Cell Therapy leading manufacturers including Pharmicell, Gencell, BlueRock Therapeutics, Cellino Biotech, Mesoblast, BioCardia, Cedars-Sinai, Stem Cells Transplant Institute, CCTRN, Help Therapeutics Co., Ltd., etc., dominate supply; the top five capture approximately % of global revenue, with Pharmicell leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Cardiovascular Diseases Stem Cell Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Cardiovascular Diseases Stem Cell Therapy Market Report

Report Metric Details
Report Name Cardiovascular Diseases Stem Cell Therapy Market
Segment by Type
  • Autologous
  • Allogeneic
Segment by Application
  • Preclinical
  • Clinical Phase 1,2
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pharmicell, Gencell, BlueRock Therapeutics, Cellino Biotech, Mesoblast, BioCardia, Cedars-Sinai, Stem Cells Transplant Institute, CCTRN, Help Therapeutics Co., Ltd., Beijing Cellapy biotechnology Co., LTD, CardioCell, Heartseed, EmCell
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Cardiovascular Diseases Stem Cell Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Cardiovascular Diseases Stem Cell Therapy Market report?

Ans: The main players in the Cardiovascular Diseases Stem Cell Therapy Market are Pharmicell, Gencell, BlueRock Therapeutics, Cellino Biotech, Mesoblast, BioCardia, Cedars-Sinai, Stem Cells Transplant Institute, CCTRN, Help Therapeutics Co., Ltd., Beijing Cellapy biotechnology Co., LTD, CardioCell, Heartseed, EmCell

What are the Application segmentation covered in the Cardiovascular Diseases Stem Cell Therapy Market report?

Ans: The Applications covered in the Cardiovascular Diseases Stem Cell Therapy Market report are Preclinical, Clinical Phase 1,2

What are the Type segmentation covered in the Cardiovascular Diseases Stem Cell Therapy Market report?

Ans: The Types covered in the Cardiovascular Diseases Stem Cell Therapy Market report are Autologous, Allogeneic

1 Study Coverage
1.1 Introduction to Cardiovascular Diseases Stem Cell Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Cardiovascular Diseases Stem Cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Autologous
1.2.3 Allogeneic
1.3 Market Segmentation by Application
1.3.1 Global Cardiovascular Diseases Stem Cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Preclinical
1.3.3 Clinical Phase 1,2
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cardiovascular Diseases Stem Cell Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Cardiovascular Diseases Stem Cell Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Cardiovascular Diseases Stem Cell Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Cardiovascular Diseases Stem Cell Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Autologous Market Size by Players
3.3.2 Allogeneic Market Size by Players
3.4 Global Cardiovascular Diseases Stem Cell Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Cardiovascular Diseases Stem Cell Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Cardiovascular Diseases Stem Cell Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Cardiovascular Diseases Stem Cell Therapy Market Size by Type (2020-2031)
6.4 North America Cardiovascular Diseases Stem Cell Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Cardiovascular Diseases Stem Cell Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Cardiovascular Diseases Stem Cell Therapy Market Size by Type (2020-2031)
7.4 Europe Cardiovascular Diseases Stem Cell Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Cardiovascular Diseases Stem Cell Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Cardiovascular Diseases Stem Cell Therapy Market Size by Type (2020-2031)
9.4 Central and South America Cardiovascular Diseases Stem Cell Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Cardiovascular Diseases Stem Cell Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Pharmicell
11.1.1 Pharmicell Corporation Information
11.1.2 Pharmicell Business Overview
11.1.3 Pharmicell Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.1.4 Pharmicell Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Pharmicell Cardiovascular Diseases Stem Cell Therapy Revenue by Product in 2024
11.1.6 Pharmicell Cardiovascular Diseases Stem Cell Therapy Revenue by Application in 2024
11.1.7 Pharmicell Cardiovascular Diseases Stem Cell Therapy Revenue by Geographic Area in 2024
11.1.8 Pharmicell Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
11.1.9 Pharmicell Recent Developments
11.2 Gencell
11.2.1 Gencell Corporation Information
11.2.2 Gencell Business Overview
11.2.3 Gencell Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.2.4 Gencell Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Gencell Cardiovascular Diseases Stem Cell Therapy Revenue by Product in 2024
11.2.6 Gencell Cardiovascular Diseases Stem Cell Therapy Revenue by Application in 2024
11.2.7 Gencell Cardiovascular Diseases Stem Cell Therapy Revenue by Geographic Area in 2024
11.2.8 Gencell Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
11.2.9 Gencell Recent Developments
11.3 BlueRock Therapeutics
11.3.1 BlueRock Therapeutics Corporation Information
11.3.2 BlueRock Therapeutics Business Overview
11.3.3 BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.3.4 BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.3.5 BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy Revenue by Product in 2024
11.3.6 BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy Revenue by Application in 2024
11.3.7 BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy Revenue by Geographic Area in 2024
11.3.8 BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
11.3.9 BlueRock Therapeutics Recent Developments
11.4 Cellino Biotech
11.4.1 Cellino Biotech Corporation Information
11.4.2 Cellino Biotech Business Overview
11.4.3 Cellino Biotech Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.4.4 Cellino Biotech Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Cellino Biotech Cardiovascular Diseases Stem Cell Therapy Revenue by Product in 2024
11.4.6 Cellino Biotech Cardiovascular Diseases Stem Cell Therapy Revenue by Application in 2024
11.4.7 Cellino Biotech Cardiovascular Diseases Stem Cell Therapy Revenue by Geographic Area in 2024
11.4.8 Cellino Biotech Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
11.4.9 Cellino Biotech Recent Developments
11.5 Mesoblast
11.5.1 Mesoblast Corporation Information
11.5.2 Mesoblast Business Overview
11.5.3 Mesoblast Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.5.4 Mesoblast Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Mesoblast Cardiovascular Diseases Stem Cell Therapy Revenue by Product in 2024
11.5.6 Mesoblast Cardiovascular Diseases Stem Cell Therapy Revenue by Application in 2024
11.5.7 Mesoblast Cardiovascular Diseases Stem Cell Therapy Revenue by Geographic Area in 2024
11.5.8 Mesoblast Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
11.5.9 Mesoblast Recent Developments
11.6 BioCardia
11.6.1 BioCardia Corporation Information
11.6.2 BioCardia Business Overview
11.6.3 BioCardia Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.6.4 BioCardia Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.6.5 BioCardia Recent Developments
11.7 Cedars-Sinai
11.7.1 Cedars-Sinai Corporation Information
11.7.2 Cedars-Sinai Business Overview
11.7.3 Cedars-Sinai Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.7.4 Cedars-Sinai Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Cedars-Sinai Recent Developments
11.8 Stem Cells Transplant Institute
11.8.1 Stem Cells Transplant Institute Corporation Information
11.8.2 Stem Cells Transplant Institute Business Overview
11.8.3 Stem Cells Transplant Institute Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.8.4 Stem Cells Transplant Institute Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Stem Cells Transplant Institute Recent Developments
11.9 CCTRN
11.9.1 CCTRN Corporation Information
11.9.2 CCTRN Business Overview
11.9.3 CCTRN Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.9.4 CCTRN Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.9.5 CCTRN Recent Developments
11.10 Help Therapeutics Co., Ltd.
11.10.1 Help Therapeutics Co., Ltd. Corporation Information
11.10.2 Help Therapeutics Co., Ltd. Business Overview
11.10.3 Help Therapeutics Co., Ltd. Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.10.4 Help Therapeutics Co., Ltd. Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Beijing Cellapy biotechnology Co., LTD
11.11.1 Beijing Cellapy biotechnology Co., LTD Corporation Information
11.11.2 Beijing Cellapy biotechnology Co., LTD Business Overview
11.11.3 Beijing Cellapy biotechnology Co., LTD Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.11.4 Beijing Cellapy biotechnology Co., LTD Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Beijing Cellapy biotechnology Co., LTD Recent Developments
11.12 CardioCell
11.12.1 CardioCell Corporation Information
11.12.2 CardioCell Business Overview
11.12.3 CardioCell Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.12.4 CardioCell Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.12.5 CardioCell Recent Developments
11.13 Heartseed
11.13.1 Heartseed Corporation Information
11.13.2 Heartseed Business Overview
11.13.3 Heartseed Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.13.4 Heartseed Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.13.5 Heartseed Recent Developments
11.14 EmCell
11.14.1 EmCell Corporation Information
11.14.2 EmCell Business Overview
11.14.3 EmCell Cardiovascular Diseases Stem Cell Therapy Product Features and Attributes
11.14.4 EmCell Cardiovascular Diseases Stem Cell Therapy Revenue and Gross Margin (2020-2025)
11.14.5 EmCell Recent Developments
12 Cardiovascular Diseases Stem Cell TherapyIndustry Chain Analysis
12.1 Cardiovascular Diseases Stem Cell Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Cardiovascular Diseases Stem Cell Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Cardiovascular Diseases Stem Cell Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
PHARMICELL
GenCell
Mesoblast Limited
BioCardia
Cedars Sinai
Heartseed
EmCell
BlueRock Therapeutics
Cellino Biotech
Stem Cells Transplant Institute
CCTRN
Help Therapeutics Co., Ltd.
Beijing Cellapy biotechnology Co., LTD
CardioCell
List of Tables
 Table 1. Global Cardiovascular Diseases Stem Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Cardiovascular Diseases Stem Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Cardiovascular Diseases Stem Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Cardiovascular Diseases Stem Cell Therapy Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Cardiovascular Diseases Stem Cell Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cardiovascular Diseases Stem Cell Therapy as of 2024)
 Table 11. Global Cardiovascular Diseases Stem Cell Therapy Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Cardiovascular Diseases Stem Cell Therapy Companies Headquarters
 Table 13. Global Cardiovascular Diseases Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Cardiovascular Diseases Stem Cell Therapy Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Cardiovascular Diseases Stem Cell Therapy High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Cardiovascular Diseases Stem Cell Therapy Growth Accelerators and Market Barriers
 Table 25. North America Cardiovascular Diseases Stem Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Cardiovascular Diseases Stem Cell Therapy Growth Accelerators and Market Barriers
 Table 27. Europe Cardiovascular Diseases Stem Cell Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Cardiovascular Diseases Stem Cell Therapy Investment Opportunities and Key Challenges
 Table 31. Central and South America Cardiovascular Diseases Stem Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Pharmicell Corporation Information
 Table 35. Pharmicell Description and Major Businesses
 Table 36. Pharmicell Product Features and Attributes
 Table 37. Pharmicell Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Pharmicell Revenue Proportion by Product in 2024
 Table 39. Pharmicell Revenue Proportion by Application in 2024
 Table 40. Pharmicell Revenue Proportion by Geographic Area in 2024
 Table 41. Pharmicell Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
 Table 42. Pharmicell Recent Developments
 Table 43. Gencell Corporation Information
 Table 44. Gencell Description and Major Businesses
 Table 45. Gencell Product Features and Attributes
 Table 46. Gencell Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Gencell Revenue Proportion by Product in 2024
 Table 48. Gencell Revenue Proportion by Application in 2024
 Table 49. Gencell Revenue Proportion by Geographic Area in 2024
 Table 50. Gencell Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
 Table 51. Gencell Recent Developments
 Table 52. BlueRock Therapeutics Corporation Information
 Table 53. BlueRock Therapeutics Description and Major Businesses
 Table 54. BlueRock Therapeutics Product Features and Attributes
 Table 55. BlueRock Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. BlueRock Therapeutics Revenue Proportion by Product in 2024
 Table 57. BlueRock Therapeutics Revenue Proportion by Application in 2024
 Table 58. BlueRock Therapeutics Revenue Proportion by Geographic Area in 2024
 Table 59. BlueRock Therapeutics Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
 Table 60. BlueRock Therapeutics Recent Developments
 Table 61. Cellino Biotech Corporation Information
 Table 62. Cellino Biotech Description and Major Businesses
 Table 63. Cellino Biotech Product Features and Attributes
 Table 64. Cellino Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Cellino Biotech Revenue Proportion by Product in 2024
 Table 66. Cellino Biotech Revenue Proportion by Application in 2024
 Table 67. Cellino Biotech Revenue Proportion by Geographic Area in 2024
 Table 68. Cellino Biotech Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
 Table 69. Cellino Biotech Recent Developments
 Table 70. Mesoblast Corporation Information
 Table 71. Mesoblast Description and Major Businesses
 Table 72. Mesoblast Product Features and Attributes
 Table 73. Mesoblast Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Mesoblast Revenue Proportion by Product in 2024
 Table 75. Mesoblast Revenue Proportion by Application in 2024
 Table 76. Mesoblast Revenue Proportion by Geographic Area in 2024
 Table 77. Mesoblast Cardiovascular Diseases Stem Cell Therapy SWOT Analysis
 Table 78. Mesoblast Recent Developments
 Table 79. BioCardia Corporation Information
 Table 80. BioCardia Description and Major Businesses
 Table 81. BioCardia Product Features and Attributes
 Table 82. BioCardia Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. BioCardia Recent Developments
 Table 84. Cedars-Sinai Corporation Information
 Table 85. Cedars-Sinai Description and Major Businesses
 Table 86. Cedars-Sinai Product Features and Attributes
 Table 87. Cedars-Sinai Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Cedars-Sinai Recent Developments
 Table 89. Stem Cells Transplant Institute Corporation Information
 Table 90. Stem Cells Transplant Institute Description and Major Businesses
 Table 91. Stem Cells Transplant Institute Product Features and Attributes
 Table 92. Stem Cells Transplant Institute Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Stem Cells Transplant Institute Recent Developments
 Table 94. CCTRN Corporation Information
 Table 95. CCTRN Description and Major Businesses
 Table 96. CCTRN Product Features and Attributes
 Table 97. CCTRN Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. CCTRN Recent Developments
 Table 99. Help Therapeutics Co., Ltd. Corporation Information
 Table 100. Help Therapeutics Co., Ltd. Description and Major Businesses
 Table 101. Help Therapeutics Co., Ltd. Product Features and Attributes
 Table 102. Help Therapeutics Co., Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Help Therapeutics Co., Ltd. Recent Developments
 Table 104. Beijing Cellapy biotechnology Co., LTD Corporation Information
 Table 105. Beijing Cellapy biotechnology Co., LTD Description and Major Businesses
 Table 106. Beijing Cellapy biotechnology Co., LTD Product Features and Attributes
 Table 107. Beijing Cellapy biotechnology Co., LTD Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Beijing Cellapy biotechnology Co., LTD Recent Developments
 Table 109. CardioCell Corporation Information
 Table 110. CardioCell Description and Major Businesses
 Table 111. CardioCell Product Features and Attributes
 Table 112. CardioCell Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. CardioCell Recent Developments
 Table 114. Heartseed Corporation Information
 Table 115. Heartseed Description and Major Businesses
 Table 116. Heartseed Product Features and Attributes
 Table 117. Heartseed Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Heartseed Recent Developments
 Table 119. EmCell Corporation Information
 Table 120. EmCell Description and Major Businesses
 Table 121. EmCell Product Features and Attributes
 Table 122. EmCell Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. EmCell Recent Developments
 Table 124. Raw Materials Key Suppliers
 Table 125. Distributors List
 Table 126. Market Trends and Market Evolution
 Table 127. Market Drivers and Opportunities
 Table 128. Market Challenges, Risks, and Restraints
 Table 129. Research Programs/Design for This Report
 Table 130. Key Data Information from Secondary Sources
 Table 131. Key Data Information from Primary Sources


List of Figures
 Figure 1. Cardiovascular Diseases Stem Cell Therapy Product Picture
 Figure 2. Global Cardiovascular Diseases Stem Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Autologous Product Picture
 Figure 4. Allogeneic Product Picture
 Figure 5. Global Cardiovascular Diseases Stem Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Preclinical
 Figure 7. Clinical Phase 1,2
 Figure 8. Cardiovascular Diseases Stem Cell Therapy Report Years Considered
 Figure 9. Global Cardiovascular Diseases Stem Cell Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Cardiovascular Diseases Stem Cell Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Cardiovascular Diseases Stem Cell Therapy Revenue Market Share by Region (2020-2031)
 Figure 13. Global Cardiovascular Diseases Stem Cell Therapy Revenue Market Share Ranking (2024)
 Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 15. Autologous Revenue Market Share by Player in 2024
 Figure 16. Allogeneic Revenue Market Share by Player in 2024
 Figure 17. Global Cardiovascular Diseases Stem Cell Therapy Revenue Market Share by Type (2020-2031)
 Figure 18. Global Cardiovascular Diseases Stem Cell Therapy Revenue Market Share by Application (2020-2031)
 Figure 19. North America Cardiovascular Diseases Stem Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 20. North America Top 5 Players Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) in 2024
 Figure 21. North America Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Type (2020 - 2031)
 Figure 22. North America Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 23. US Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 24. Canada Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 25. Mexico Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 26. Europe Cardiovascular Diseases Stem Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. Europe Top 5 Players Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) in 2024
 Figure 28. Europe Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 29. Europe Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 30. Germany Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 31. France Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 32. U.K. Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 33. Italy Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 34. Russia Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Top 8 Players Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) in 2024
 Figure 37. Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 38. Asia-Pacific Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 39. Indonesia Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 40. Japan Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 41. South Korea Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 42. Australia Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 43. India Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 44. Indonesia Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 45. Vietnam Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 46. Malaysia Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 47. Philippines Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 48. Singapore Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 49. Central and South America Cardiovascular Diseases Stem Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Central and South America Top 5 Players Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) in 2024
 Figure 51. Central and South America Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 52. Central and South America Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 53. Brazil Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 54. Argentina Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 55. Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 56. Middle East and Africa Top 5 Players Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) in 2024
 Figure 57. South America Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 58. Middle East and Africa Cardiovascular Diseases Stem Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 59. GCC Countries Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 60. Israel Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 61. Egypt Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 62. South Africa Cardiovascular Diseases Stem Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 63. Cardiovascular Diseases Stem Cell Therapy Industry Chain Mapping
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Cardiology Stem Cells Market Research Report 2024
Global Stem Cell Therapy for Pets Market Research Report 2024
Global Cell Therapy Regenerative Medicine Market Research Report 2025
Placental Stem Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Stem Cell Therapy Market Insights Forecast to 2030
Global Cardiac Disease Stem Cell Therapy Market Research Report 2024
Hematopoietic Stem Cells Transplantation Market
Global Animal Stem Cell Therapy Market Research Report 2025
Global Pet Stem Cells Market Insights Forecast to 2030
Global Stem Cell Treatments Market Insights Forecast to 2030
Global Canine Stem Cell Therapy Market Research Report 2024
Transplantation of Hematopoietic Stem Cells Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Transplantation of Multipotent Hematopoietic Stem Cells Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematopoietic Stem Cells Transplantation Consumables and Storage Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Umbilical Cord Blood Stem Cell Bank Market Research Report 2024
Global Mesenchymal Stem Cell Drugs Market Research Report 2024
Global Stem Cell Therapy for Infertility Market Research Report 2024
Global Stem Cell Services Market Insights Forecast to 2030
Global Rheumatoid Arthritis Stem Cell Therapy Market Research Report 2024
Global Mesenchymal Stem Cell Injection Market Research Report 2024

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32P14840
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Digital Platform for Chronic Kidney Disease (CKD) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-20V18395
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Continuous Glucose Monitoring Sensor Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32G20014
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions